Latest Articles

Thanks to the rise of AI, HTS for drug discovery is taking a more intelligent, computational approach, with tools that allow scientists to pinpoint the most promising drug candidates faster. Explore how this evolution will be further enhanced by a shift from 2D to 3D biological models such as organoids.

An organ-on-a-chip is a model system containing engineered cells grown inside microfluidic chips. This article will highlight some recent advances in organ-on-a-chip technology and how they are being used to improve disease modeling and drug discovery.

Using data provided by Intercontinental Exchange, My Green Lab has produced a report providing key insights into the current state of the sector’s carbon emissions. James Connelly highlights some of the key findings and their significance.

This article explores several examples of how comprehensive modeling tools and expert guidance can help determine what specific adaptations can optimize trials.

The COVID-19 global pandemic has left in its wake a baffling array of symptoms, affecting many survivors for months after the virus has run its course. This article explores the current state of long COVID research.

Dr. Darrell Green's best friend, Ben, developed bone cancer and passed away just before his 14th birthday. This profile article explores how this experience stayed with Green, and has propelled his work towards a new treatment for bone cancer.

Two-dimensional liquid chromatography (2D-LC) offers extra separation power for complex and challenging samples and now has an important place in industry as well academia thanks to important advances. But this is by no means the end of the story.

Chronic sleep disruption (CSD) has been shown to promote pain. Now, a team of scientists have shed light on some of the brain regions and signaling molecules that may be responsible, offering potential avenues for therapeutic investigation.

Antimicrobial resistance (AMR) is threatening the effective treatment and prevention of a wide range of infections, with serious potential consequences for health and the economy. We spoke to Dr. Alaa Riezk, research associate at the Centre for Antimicrobial Optimisation (CAMO), Imperial College London, about the problem of usage and dosage of antimicrobials and AMR and how he and the team are working to address it.

This article focuses on the use of high-throughput screening approaches in drug discovery and discusses the latest developments in this area.